President Biden’s Proposal To Expand Medicare Price Controls A Sign Of Things To Come
Executive Summary
Even though it is unlikely that the policies will succeed in the currently divided Congress, the proposal reinforces industry’s concerns that once a foundation for Medicare price negotiation is established, policymakers will try to build on it.
You may also be interested in...
Medicare Negotiation And The Politics Of Drug Pricing
Medicare pricing decisions will become ‘highly politicized,’ Scott Gottlieb predicts. The former FDA commissioner and CMS official also believes the program should rely on outside health technology assessment groups, and he offers his opinions on how negotiation will (or won’t) change patent litigation.
Ease The Pain – Making Payment Models, Tech, Integration Work For Patients
Multiple payment models, including differential pricing for pooled purchases, and technology-based healthcare platforms are some of the ways to build a patient-centric ecosystem said officials from Roche, VCs and non-government bodies at a recent conference
Medicare Price Inflation Rebates Levied On 27 Part B Drugs In First Round; Pfizer Tops The List
Biden Administration releases first list of Part B drugs subject to inflation rebates; others to follow on quarterly basis. Medicare won’t invoice sponsors until 2025, but patients could see coinsurance reductions next month.